

NCCN Acute Myeloid Leukemia Guidelines V.1.2011 – Update Teleconference – 05/21/10

Guideline Page and Request	Panel Discussion	References	Vote	
			YES	NO
<p>AML-3 Internal request: Institutional Review comment requesting the addition of the North American Intergroup Protocol C9710 added as a regimen option in consolidation therapy.</p>	<p>The North American Intergroup Protocol C9710 was designed to evaluate the benefit and toxicity of two 25 day courses of arsenic trioxide as first remission therapy for newly diagnosed patients with APL. This was a positive randomized phase III trial that demonstrated significant improvements in event free survival and overall survival as compared to the standard arm. Based on this information the consolidation regimen from this trial was added as an option in patients with APL.</p>	<p>Powell BL, Moser B, Stock W, et al. Effect of consolidation with arsenic trioxide on event-free survival and overall survival among patients with newly diagnosed acute promyelocytic leukemia: North American Intergroup Protocol C9710. J Clin Oncol, 2007 Annual Meeting Proceedings Part I;25(18s):abstr 2. Powell BL, et al. Arsenic trioxide improves event-free and over-all survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010 (in press).</p>	15	0
<p>AML-F Internal request: Institutional review comment requesting the expansion of salvage therapy options for patients in relapse.</p>	<p>Based upon the studies listed in the references column, the following regimens were added to a new page listing options for salvage therapy: Cladribine + cytarabine + GCSF ± mitoxantrone or idarubicin Mitoxantrone + etoposide + cytarabine (MEC)</p>	<p>Martin MG, Welch JS, Augustin K, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma 2009;9(4):298-301. Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol 2008;80(2):115-126. Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991 Jul;9(7):1210-1214.</p>	15	0